Enlivex Ltd. (ENLV): R&D Expense
$9.20M
Year ended 2025-12-31
-21.0%
3-year compound annual growth
+8.6%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $9.20M | -13.4% | 2026-03-25, From 2025-01-01 |
| 2024-12-31 | $10.62M | -44.1% | 2026-03-25, From 2024-01-01 |
| 2023-12-31 | $19.01M | +1.7% | 2026-03-25, From 2023-01-01 |
| 2022-12-31 | $18.69M | +45.1% | 2025-04-30, From 2022-01-01 |
| 2021-12-31 | $12.88M | +111.6% | 2024-04-30, From 2021-01-01 |
| 2020-12-31 | $6.09M | +8.6% | 2023-04-10, From 2020-01-01 |
| 2019-12-31 | $5.60M | +39.6% | 2022-04-29, From 2019-01-01 |
| 2018-12-31 | $4.01M | n/c | 2021-04-30, From 2018-01-01 |
| 2017-12-31 | $1.69M | n/c | 2020-04-30, From 2017-01-01 |
| 2016-12-31 | $8.88M | +15.4% | 2020-01-23, From 2016-01-01 |
| 2015-12-31 | $7.69M | +73.2% | 2018-04-23, From 2015-01-01 |
| 2014-12-31 | $4.44M | +506.7% | 2017-02-24, From 2014-01-01 |
| 2013-12-31 | $732.0K | +422.9% | 2016-03-29, From 2013-01-01 |
| 2012-12-31 | $140.0K | n/a | 2015-03-31, From 2012-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Enlivex Ltd. (ENLV) | 2025-12-31 | $9.20M | -13.4% |
| Insmed Inc (INSM) | 2025-12-31 | $771.09M | +28.9% |
| Alkermes plc. (ALKS) | 2025-12-31 | $323.96M | +32.1% |
| Opko Health, Inc. (OPK) | 2025-12-31 | $124.03M | +17.9% |
| PTC Therapeutics, Inc. (PTCT) | 2025-12-31 | $455.25M | -14.8% |
| HUTCHMED (China) Ltd (HCM) | 2025-12-31 | $148.29M | -30.1% |
| Collegium Pharmaceutical, Inc (COLL) | 2024-12-31 | $0 | n/a |
| Innoviva, Inc. (INVA) | 2025-12-31 | $30.60M | +124.1% |
| Amphastar Pharmaceuticals, Inc. (AMPH) | 2025-12-31 | $85.84M | +16.1% |
Compare ENLV, INSM, ALKS, OPK side by side · Screen every company in Pharmaceutical Preparations ↗